Evandro de Azambuja

37.9k total citations · 9 hit papers
351 papers, 15.4k citations indexed

About

Evandro de Azambuja is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Evandro de Azambuja has authored 351 papers receiving a total of 15.4k indexed citations (citations by other indexed papers that have themselves been cited), including 294 papers in Oncology, 133 papers in Cancer Research and 117 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Evandro de Azambuja's work include HER2/EGFR in Cancer Research (168 papers), Breast Cancer Treatment Studies (120 papers) and Cancer Treatment and Pharmacology (98 papers). Evandro de Azambuja is often cited by papers focused on HER2/EGFR in Cancer Research (168 papers), Breast Cancer Treatment Studies (120 papers) and Cancer Treatment and Pharmacology (98 papers). Evandro de Azambuja collaborates with scholars based in Belgium, Italy and United States. Evandro de Azambuja's co-authors include Martine Piccart, Christos Sotiriou, Matteo Lambertini, Giuseppe Viale, Sherene Loi, Gilberto de Castro, Fátima Cardoso, Hatem A. Azim, Marianne Paesmans and Richard D. Gelber and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Evandro de Azambuja

329 papers receiving 15.2k citations

Hit Papers

Prognostic and Predictive Value of Tumor-Infiltrating Lym... 2007 2026 2013 2019 2013 2017 2007 2017 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
    2013 1.2k citations Sherene Loi, Giuseppe Viale et al. Journal of Clinical Oncology profile →
  2. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    2017 918 citations Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine profile →
  3. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
    2007 724 citations Evandro de Azambuja, Fátima Cardoso et al. British Journal of Cancer profile →
  4. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    2017 688 citations Martine Piccart, Richard D. Gelber et al. profile →
  5. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
    2012 595 citations Evandro de Azambuja et al. Annals of Oncology profile →
  6. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
    2015 432 citations Christine Campbell, Paolo Nucíforo et al. JAMA Oncology profile →
  7. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
    2017 426 citations Evandro de Azambuja et al. Annals of Oncology profile →
  8. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
    2018 303 citations Francesca Poggio, Marco Bruzzone et al. Annals of Oncology profile →
  9. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer
    2021 168 citations Maria Alice Franzoi, Elisa Agostinetto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evandro de Azambuja Belgium 58 10.7k 4.7k 3.6k 3.1k 2.5k 351 15.4k
Eitan Amir Canada 57 8.8k 0.8× 3.6k 0.8× 3.9k 1.1× 2.6k 0.8× 1.5k 0.6× 416 15.4k
Brian Leyland‐Jones United States 53 11.6k 1.1× 4.6k 1.0× 3.3k 0.9× 5.7k 1.8× 4.1k 1.6× 218 18.4k
P. Fumoleau France 61 9.6k 0.9× 4.4k 0.9× 2.7k 0.7× 3.3k 1.1× 2.3k 0.9× 326 14.3k
Aňa Lluch Spain 55 10.3k 1.0× 6.1k 1.3× 2.5k 0.7× 4.1k 1.3× 2.7k 1.1× 306 14.7k
Melody Cobleigh United States 39 10.5k 1.0× 3.8k 0.8× 2.8k 0.8× 4.3k 1.4× 3.0k 1.2× 131 14.7k
Sabino De Placido Italy 64 7.8k 0.7× 3.7k 0.8× 4.5k 1.3× 4.4k 1.4× 1.6k 0.6× 381 14.0k
Debu Tripathy United States 53 10.7k 1.0× 3.1k 0.7× 3.7k 1.0× 4.2k 1.4× 4.3k 1.7× 422 15.9k
Christoph Zielinski Austria 69 10.1k 0.9× 2.6k 0.6× 5.7k 1.6× 5.0k 1.6× 2.0k 0.8× 499 20.8k
Karen A. Gelmon Canada 73 15.9k 1.5× 7.0k 1.5× 6.6k 1.8× 5.6k 1.8× 2.3k 0.9× 393 23.8k
Francisco J. Esteva United States 68 11.6k 1.1× 4.6k 1.0× 3.2k 0.9× 7.0k 2.3× 4.9k 1.9× 280 18.0k

Countries citing papers authored by Evandro de Azambuja

Since Specialization
Citations

This map shows the geographic impact of Evandro de Azambuja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evandro de Azambuja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evandro de Azambuja more than expected).

Fields of papers citing papers by Evandro de Azambuja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evandro de Azambuja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evandro de Azambuja. The network helps show where Evandro de Azambuja may publish in the future.

Co-authorship network of co-authors of Evandro de Azambuja

This figure shows the co-authorship network connecting the top 25 collaborators of Evandro de Azambuja. A scholar is included among the top collaborators of Evandro de Azambuja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evandro de Azambuja. Evandro de Azambuja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arecco, Luca, Elisa Agostinetto, Maria Alice Franzoi, et al.. (2025). Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance. ESMO Open. 10(5). 105057–105057. 3 indexed citations
2.
Baelen, Karen Van, François Richard, Maria Margarete Karsten, et al.. (2025). Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study. Breast Cancer Research. 27(1). 106–106. 1 indexed citations
3.
Maurer, Christian, Elisa Agostinetto, Lieveke Ameye, et al.. (2025). Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Research and Treatment. 212(1). 57–69. 1 indexed citations
4.
Debien, Véronique, Evandro de Azambuja, & Martine Piccart. (2023). Optimizing treatment for HER2-positive HR-positive breast cancer. Cancer Treatment Reviews. 115. 102529–102529. 11 indexed citations
5.
Marta, Guilherme Nader, Véronique Debien, Daniel Eiger, et al.. (2022). Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. 127(10). 1799–1807. 1 indexed citations
6.
Agostinetto, Elisa, Véronique Debien, Guilherme Nader Marta, et al.. (2021). CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer. European Journal of Clinical Investigation. 51(7). e13535–e13535. 19 indexed citations
7.
Agostinetto, Elisa, Rafael Caparica, Marco Bruzzone, et al.. (2021). CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis. ESMO Open. 6(2). 100091–100091. 15 indexed citations
8.
Cesca, Marcelle Goldner, et al.. (2020). HER2-positive advanced breast cancer treatment in 2020. Cancer Treatment Reviews. 88. 102033–102033. 84 indexed citations
9.
Pondé, Noam, Lieveke Ameye, Matteo Lambertini, et al.. (2020). Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. European Journal of Cancer. 126. 65–73. 58 indexed citations
10.
Cosimo, Serena Di, Valentina Appierto, Sara Pizzamiglio, et al.. (2019). Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clinical Cancer Research. 25(13). 3887–3895. 46 indexed citations
11.
Caparica, Rafael, Marco Bruzzone, Francesca Poggio, et al.. (2018). Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment. 174(1). 27–37. 34 indexed citations
12.
Powles, Ryan L., David Redmond, Christos Sotiriou, et al.. (2018). Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. JAMA Oncology. 4(11). e181564–e181564. 13 indexed citations
13.
14.
Minckwitz, Gϋnter von, Marion Procter, Evandro de Azambuja, et al.. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine. 377(2). 122–131. 918 indexed citations breakdown →
15.
Pinto, Ana Catarina, Fernando Ferreira‐Santos, Evandro de Azambuja, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 8. 425–425. 16 indexed citations
16.
Loi, Sherene, Urania Dafni, Dimitris Karlis, et al.. (2016). Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology. 2(8). 1040–1040. 65 indexed citations
17.
Azambuja, Evandro de, Dimitrios Zardavas, Marc Lemort, et al.. (2013). Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Annals of Oncology. 24(12). 2985–2989. 21 indexed citations
18.
Zardavas, Dimitrios, Felipe Ades, & Evandro de Azambuja. (2013). Clinical practice-changing trials: the HERA study paradigm. Expert Review of Anticancer Therapy. 13(11). 1249–1256. 4 indexed citations
19.
Metzger, Otto, Andrew Tutt, Evandro de Azambuja, et al.. (2012). Dissecting the Heterogeneity of Triple-Negative Breast Cancer. Journal of Clinical Oncology. 30(15). 1879–1887. 356 indexed citations
20.
Ismael, Gustavo, Daniela Dornelles Rosa, Evandro de Azambuja, Sofía Braga, & Martine Piccart. (2007). Trastuzumab (Herceptin) for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America. 21(2). 239–256. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eitan Amir Breakdown of academic impact, for papers by Brian Leyland‐Jones Breakdown of academic impact, for papers by P. Fumoleau Breakdown of academic impact, for papers by Aňa Lluch Breakdown of academic impact, for papers by Melody Cobleigh Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Debu Tripathy Breakdown of academic impact, for papers by Christoph Zielinski Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Francisco J. Esteva
Rankless by CCL
2026